Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
Table 3
Characteristics of patients included in the second supplementary analysis.
RT group (n = 35)
Non-RT group (n = 229)
Standardized difference†
Number or mean (SD)†
(%)†
Number or mean (SD)†
(%)†
Before PSW
After PSW
Age (years)
62.97 (8.58)
64.60 (8.30)
0.193
≈0
Sex
Female
20
(57)
158
(69)
0.247
≈0
Male
15
(43)
71
(31)
Residency
Non-northern
18
(51)
160
(70)
0.384
≈0
Northern
17
(49)
69
(30)
Comorbidity
<1
32
(91)
204
(89)
0.079
≈0
≥1
3
(9)
25
(11)
BMI (kg/m2)
25.23 (5.33)
24.01 (3.71)
0.266
≈0
Social-economic status
Minimum wage or lower
6
(17)
70
(31)
0.319
≈0
Higher
29
(83)
159
(69)
Smoking
No
25
(71)
178
(78)
0.145
≈0
Yes
10
(29)
51
(22)
Clinical T-stage
T1–T2
14
(40)
95
(41)
0.030
≈0
T3–T4
21
(60)
134
(59)
Clinical N-stage
N0–N2
9
(26)
49
(21)
0.030
≈0
N3
26
(74)
180
(79)
Tumor size (mm)
45.46 (19.12)
42.97 (20.74)
0.125
≈0
ECOG PS
0-1
31
(89)
212
(93)
0.137
≈0
2
4
(11)
17
(7)
BMI, body mass index; ECOG PS, eastern cooperative oncology group performance status; PS, propensity score; RT, radiotherapy; SD, standard deviation. †Rounded.
